Upstate Active Clinical Trials

Study Title:

A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, FLEXIBLE-DOSE, 27-WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAVAPADON IN EARLY PARKINSON’S DISEASE

What is the purpose of the study? (in Layman's terms, please describe the study)

To assess the efficacy of tavapadon in subjects with early PD.

Upstate Institutional Review Board (IRB) Number:

1554516

Patient Age Group:

Adults

Principal Investigator:

Dragos L Mihaila

What is involved if I participate?

• How long is the study?
  Approximately 7 months.

ClinicalTrials.Gov ID:

NCT04223193

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Marielle N Posmik
Phone: 315-464-1670
Email: [email protected]

Return to Previous Page || Search Again